Why Chronic Pain
Neuropathic pain affects 7–10% of the global population, disproportionately impacting women and the elderly. It commonly arises from diabetes, chemotherapy, or herpes zoster, resulting in peripheral nerve damage and intensified pain signaling. Existing treatments, such as opioids, were originally developed for other conditions and offer only partial pain relief while being associated with significant side effects. The critical unmet need for safer more effective therapies highlights the necessity for the advancement of innovative methods for treating neuropathic pain.
PICK1: A NOVEL TARGET
At Zyneyro, we develop innovative therapies that target the protein PICK1, a novel therapeutic target, which we have identified through years of research as playing a critical role in the development of chronic pain.
Our proprietary synthetic peptides that are specifically optimized to bind PICK1 in the peripheral nervous system can significantly improve chronic pain management, as demonstrated in our preclinical animal studies.
THE IMPACT
Our synthetic inhibitors are designed to provide fast-acting, temporary relief from evoked and spontaneous pain, which have been demonstrated and validated in animal models of neuropathic pain, inflammatory pain, and diabetic related pain. Importantly, this approach has shown no negative effects on normal pain perception or cognitive function. Our therapy thereby circumvents the addiction and abuse liability seen with treatments currently on the market.
